Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07724366) titled 'A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis' on July 21.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Condition:
Psoriasis
Intervention:
Drug: TQH3906 capsules
Drug: Deucravacitinib tablets 6 mg
Drug: TQH3906 Capsules placebo
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enro...